EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Efficacy and safety of a propafenone-centered stepwise cardioversion regimen for first-onset pediatric paroxysmal supraventricular tachycardia: an age-stratified clinical effectiveness study

Min Zhang, Hanlan Jiang, Hongyong Wang, Xingfeng Cheng

Frontiers in Pediatrics · 17.11.2026 · 14

DOI: 10.3389/fped.2026.1976367 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pediatrics, online erschienen am 17.11.2026. Verfasst von Min Zhang und 3 weiteren Autor:innen. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Paroxysmal supraventricular tachycardia (PSVT) is the most common symptomatic arrhythmia in children. While international guidelines recommend adenosine as first-line therapy and caution against propafenone use in neonates, propafenone is widely used for acute cardioversion across pediatric age groups in China, with limited real-world efficacy and safety data in neonates and young infants.

Methods

This single-center retrospective clinical effectiveness study included 70 children with first-onset acute PSVT treated with a propafenone-centered stepwise cardioversion regimen. The 24-hour cardioversion efficacy was evaluated primarily in the per-protocol set (PPS, n = 45), with the full analysis set (FAS, n = 70) used for sensitivity verification. Firth's penalized logistic regression was applied to identify predictors of high treatment difficulty (requiring second-line or higher interventions), and the Jonckheere–Terpstra test to assess age-related trends in myocardial injury biomarkers. The discriminative performance of the prediction model was evaluated using receiver operating characteristic (ROC) curve analysis.

Results

The stepwise cardioversion regimen achieved an overall 24-hour sinus rhythm conversion rate of 100%. Propafenone achieved an overall cardioversion success rate of 55.7% in the FAS (all first-line administration) and 71.1% for standardized first-line monotherapy in the PPS. All 4 neonates required escalation to second-line or higher interventions, with no response to first-line propafenone monotherapy in the 2 exposed cases. Treatment difficulty decreased significantly with advancing age ( P = 0.001), as did serum hs-cTnT ( P = 0.004), CK-MB ( P < 0.001) and NT-proBNP ( P < 0.001). In multivariable Firth's penalized regression (68 complete cases, 4 core covariates), NT-proBNP was an independent predictor of higher treatment difficulty ( P < 0.001). The prediction model yielded an AUC of 0.718 (95%CI:0.597–0.839, P = 0.002) with moderate exploratory discriminative performance. No severe treatment-related adverse events were observed.

Conclusions

The propafenone-centered stepwise cardioversion regimen achieves favorable efficacy and acceptable short-term safety for first-onset PSVT in children aged ≥1year. Evidence in neonates remains very limited, so routine first-line propafenone is not recommended in this age group. The multivariable model offers moderate exploratory predictive value, with NT-proBNP identified as an independent predictor of treatment difficulty in this cohort.

Zitieren

APA

Zhang, M., Jiang, H., Wang, H., & Cheng, X. (2026). Efficacy and safety of a propafenone-centered stepwise cardioversion regimen for first-onset pediatric paroxysmal supraventricular tachycardia: an age-stratified clinical effectiveness study. Frontiers in Pediatrics, 14. https://doi.org/10.3389/fped.2026.1976367

Vancouver

Zhang M, Jiang H, Wang H, Cheng X. Efficacy and safety of a propafenone-centered stepwise cardioversion regimen for first-onset pediatric paroxysmal supraventricular tachycardia: an age-stratified clinical effectiveness study. Frontiers in Pediatrics. 2026;14. doi:10.3389/fped.2026.1976367

BibTeX
@article{Zhang2026,
  author = {Zhang, Min and Jiang, Hanlan and Wang, Hongyong and Cheng, Xingfeng},
  title = {Efficacy and safety of a propafenone-centered stepwise cardioversion regimen for first-onset pediatric paroxysmal supraventricular tachycardia: an age-stratified clinical effectiveness study},
  journal = {Frontiers in Pediatrics},
  year = {2026},
  volume = {14},
  doi = {10.3389/fped.2026.1976367}
}
Kostenlos starten →